Biological
IMC-002
IMC-002 is a biological therapy with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Not yet recruiting1
Recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
not_yet_recruiting133%
recruiting133%
completed133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingphase_1
A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
NCT05276310
not_yet_recruitingphase_1
A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients
NCT06557174
completedphase_1
A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas
NCT04306224
Clinical Trials (3)
Showing 3 of 3 trials
NCT05276310Phase 1
A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
NCT06557174Phase 1
A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients
NCT04306224Phase 1
A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3